Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$20.13 -1.3%	$23.43	$12.21 ▼ $40.70	$563.58M	-0.2	750,603 shs	503,622 shs
MIST Milestone Pharmaceuticals	$1.81 +2.3%	$1.71	$0.63 ▼ $2.75	$153.83M	0.52	1.71 million shs	940,009 shs
SAGE Sage Therapeutics	$8.68	$8.92	$4.62 ▼ $11.44	$543.54M	0.26	3.63 million shs	N/A
SVRA Savara	$3.27 -0.6%	$2.54	$1.89 ▼ $4.70	$565.19M	0.4	1.25 million shs	843,236 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+2.20%	+1.24%	-23.28%	-9.57%	-44.63%
MIST Milestone Pharmaceuticals	+4.73%	+7.93%	+14.19%	+11.32%	+20.41%
SAGE Sage Therapeutics	0.00%	0.00%	-1.14%	+33.13%	+7.03%
SVRA Savara	-0.60%	+6.47%	+23.68%	+46.88%	-23.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	1.9252 of 5 stars	3.4	0.0	0.0	2.3	2.5	0.6
MIST Milestone Pharmaceuticals	1.7102 of 5 stars	3.1	1.0	0.0	2.6	2.5	0.0
SAGE Sage Therapeutics	3.6895 of 5 stars	2.0	5.0	4.1	2.1	1.7	0.6
SVRA Savara	2.4551 of 5 stars	3.4	0.0	0.0	3.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$46.13	129.14% Upside
MIST Milestone Pharmaceuticals	2.25	Hold	$5.00	176.24% Upside
SAGE Sage Therapeutics	1.93	Reduce	$7.85	-9.56% Downside
SVRA Savara	2.83	Moderate Buy	$6.17	88.58% Upside

Current Analyst Ratings Breakdown

Latest MIST, ANAB, SVRA, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	SVRA Savara	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$5.00 ➝ $6.00
8/15/2025	SVRA Savara	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$2.00 ➝ $5.00
8/12/2025	ANAB AnaptysBio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$18.00 ➝ $20.00
8/7/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $45.00
7/24/2025	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $80.00
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$123.16M	4.58	N/A	N/A	($1.60) per share	-12.58
MIST Milestone Pharmaceuticals	$1M	153.83	N/A	N/A	($0.21) per share	-8.62
SAGE Sage Therapeutics	$41.24M	13.18	N/A	N/A	$5.89 per share	1.47
SVRA Savara	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.48	N/A	N/A	N/A	-107.66%	-366.98%	-30.58%	11/4/2025 (Estimated)
MIST Milestone Pharmaceuticals	-$41.52M	-$0.84	N/A	N/A	N/A	N/A	-1,672.29%	-83.09%	11/11/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$4.89	N/A	N/A	N/A	-427.78%	-67.10%	-58.42%	11/4/2025 (Estimated)
SVRA Savara	-$95.88M	-$0.50	N/A	N/A	N/A	N/A	-69.05%	-54.84%	11/11/2025 (Estimated)

Latest MIST, ANAB, SVRA, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q1 2025	SVRA Savara	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A
8/12/2025	Q2 2025	MIST Milestone Pharmaceuticals	-$0.18	-$0.20	-$0.02	-$0.20	N/A	N/A
8/6/2025	Q2 2025	ANAB AnaptysBio	-$1.50	-$1.34	+$0.16	-$1.34	$11.55 million	$22.26 million
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	-$0.79	+$0.17	-$0.79	$16.69 million	$31.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.22	8.22
MIST Milestone Pharmaceuticals	4.06	4.97	4.97
SAGE Sage Therapeutics	N/A	9.16	9.13
SVRA Savara	0.25	11.08	11.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
MIST Milestone Pharmaceuticals	86.18%
SAGE Sage Therapeutics	99.22%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
MIST Milestone Pharmaceuticals	19.50%
SAGE Sage Therapeutics	5.50%
SVRA Savara	5.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	28.00 million	18.62 million	Optionable
MIST Milestone Pharmaceuticals	30	84.99 million	68.42 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
SVRA Savara	20	172.84 million	163.63 million	Optionable

MIST, ANAB, SVRA, and SAGE Headlines

Recent News About These Companies

Savara Announces Participation in Upcoming Investor Healthcare Conferences

August 26 at 4:05 PM | businesswire.com

Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough

August 24, 2025 | finance.yahoo.com

Savara to Present Key Research on Rare Lung Disease at ERS Congress 2025

August 24, 2025 | msn.com

Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough

August 23, 2025 | insidermonkey.com

New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

August 22, 2025 | finance.yahoo.com

3 Best Stocks to Buy Now, 8/22/2025, According to Top Analysts

August 22, 2025 | msn.com

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

August 20, 2025 | businesswire.com

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP ...

August 19, 2025 | dutchnews.nlD

Savara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 19, 2025 | americanbankingnews.com

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

August 18, 2025 | businesswire.com

Savara (NASDAQ:SVRA) Shares Gap Up Following Analyst Upgrade

August 17, 2025 | marketbeat.com

Savara (NASDAQ:SVRA) Given New $6.00 Price Target at Oppenheimer

August 17, 2025 | marketbeat.com

Savara (NASDAQ:SVRA) Upgraded at HC Wainwright

August 17, 2025 | marketbeat.com

Oppenheimer Issues Positive Forecast for Savara (NASDAQ:SVRA) Stock Price

August 17, 2025 | americanbankingnews.com

Savara (NASDAQ:SVRA) Stock Price Up 8% - Should You Buy?

August 16, 2025 | marketbeat.com

HC Wainwright & Co. Upgrades Savara (SVRA)

August 16, 2025 | msn.com

Savara (NASDAQ:SVRA) Releases Earnings Results, Misses Expectations By $0.02 EPS

August 15, 2025 | marketbeat.com

Savara upgraded to Buy from Neutral at H.C. Wainwright

August 15, 2025 | msn.com

H.C. Wainwright upgrades Savara to Buy on resubmission prospects

August 15, 2025 | msn.com

Savara upgraded at H.C. Wainwright on potential refiling of marketing application

August 15, 2025 | msn.com

Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

August 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MIST, ANAB, SVRA, and SAGE Company Descriptions

AnaptysBio NASDAQ:ANAB

$20.13 -0.27 (-1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$20.12 -0.01 (-0.05%)

As of 04:31 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Milestone Pharmaceuticals NASDAQ:MIST

$1.81 +0.04 (+2.26%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 -0.02 (-0.83%)

As of 05:42 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Sage Therapeutics NASDAQ:SAGE

$8.68 0.00 (0.00%)

As of 07/31/2025

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Savara NASDAQ:SVRA

$3.27 -0.02 (-0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$3.22 -0.05 (-1.53%)

As of 05:34 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time